source
- Roche's Genentech signs up to $2.3B deal with Hanmi for weight-loss drug that preserves lean massRoche, through its Genentech subsidiary, has entered a licensing agreement with South Korea's Hanmi Pharm that could be worth up to $2.3 billion, including a $190 million upfront payment. The deal…
- Roche commits to lean-mass preservation with Hanmi obesity dealFor $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.BioPharma Dive · 5h ago↗ source